Access to a cannabis-based medicine derived from a non-psychoactive component of the cannabis plant will be made available to NSW children with severe treatment-resistant epilepsy. The medicine (named Epidiolex) will be prescribed at Sydney Children’s Hospital in Randwick.
The use of Epidiolex falls under the Compassionate Access Scheme which is part of an agreement between the NSW Government and GW Pharmaceuticals, the manufacturer of Epidiolex.
This is one of many trials being undertaken throughout NSW documenting the effectiveness of cannabis for therapeutic purposes. Over the next five years, the NSW Government will invest $9 million on clinical trials of cannabis. Other trials will examine the effectiveness of cannabis for the relief of chemotherapy-induced nausea and other symptoms affecting the terminally ill.
For more information, click here.